FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease

SAN FRANCISCO, June 07, 2018 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced the completion of patient enrollment in the Phase 3 studies supporting the U.S. new drug application (NDA) submission for roxadustat in anemia associated with chronic kidney disease (CKD). The Phase 3 clinical program is evaluating the use of roxadustat for the treatment of anemia in both dialysis-dependent and non-dialysis-dependent CKD patients.
“We are pleased to have achieved this critical step in our roxadustat Phase 3 clinical program, and we look forward to reporting topline results from these studies by the end of this year, with pooled safety analyses availa…

Source: Original Article